Nasus Pharma (NSRX) Total Current Liabilities (2024 - 2025)
Nasus Pharma (NSRX) reported Total Current Liabilities of $2.2 million for Q4 2025, down 44.95% on a YoY basis from $3.9 million in Q4 2024, and down 56.33% quarter-over-quarter from $5.0 million in Q2 2025.
Nasus Pharma (NSRX) Total Current Liabilities (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Total Current Liabilities for 2 years, with the latest figure at $2.2 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities fell 44.95% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (down 44.95% YoY), and the FY2025 full-year result was $2.2 million, down 44.95% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $2.2 million, down from $5.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $5.0 million in Q2 2025, with the low at $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | 2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.16 Mn |
| Jun 30, 2025 | 4.95 Mn |
| Dec 31, 2024 | 3.93 Mn |